Journal: Molecules

Article Title: Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions

doi: 10.3390/molecules28248064

Figure Lengend Snippet: Active and completed clinical trials conducted on JAKi for the treatment of atopic dermatitis according to ClinicalTrials.gov .

Article Snippet: Delgocitinib , ≥18 yo , JAK1, JAK2, JAK3, TYK2 , Topical , Phase 2 , NCT03725722 , LEO Pharma.

Techniques: Clinical Proteomics

Journal: Molecules

Article Title: Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions

doi: 10.3390/molecules28248064

Figure Lengend Snippet: Active and completed clinical trials conducted on JAKi for the treatment of alopecia areata according to ClinicalTrials.gov .

Article Snippet: Delgocitinib , ≥18 yo , JAK1, JAK2, JAK3, TYK2 , Topical , Phase 2 , NCT03725722 , LEO Pharma.

Techniques: Clinical Proteomics

Journal: Molecules

Article Title: Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions

doi: 10.3390/molecules28248064

Figure Lengend Snippet: Active and completed clinical trials conducted on the use of JAK inhibitors w hidradenitis suppurativa, chronic hand eczema, diffuse cutaneous systemic scleroderma, granuloma annulare, dermatomyositis, lichen planus and lupus erythematosus according to ClinicalTrials.gov .

Article Snippet: Delgocitinib , ≥18 yo , JAK1, JAK2, JAK3, TYK2 , Topical , Phase 2 , NCT03725722 , LEO Pharma.

Techniques: Clinical Proteomics

Journal: American Journal of Clinical Dermatology

Article Title: What’s New in Topicals for Atopic Dermatitis?

doi: 10.1007/s40257-022-00712-0

Figure Lengend Snippet: Overview of new topical agents for atopic dermatitis

Article Snippet: Based on these results, LEO Pharma initiated the first phase III clinical trial with delgocitinib cream in May 2021.

Techniques: Inhibition, Cream, Ointment

Journal: Allergologie Select

Article Title: Janus kinase inhibitors for the therapy of atopic dermatitis

doi: 10.5414/ALX02272E

Figure Lengend Snippet: The different topical and systemic JAK inhibitors with the different doses, dosing frequencies and current phase in clinical trials.

Article Snippet: Last year, delgocitinib (Corectim, Japan Tobacco Inc., Tokyo, Japan) was approved as the first topical JAK inhibitor in Japan for the indication “atopic dermatitis”.

Techniques: Formulation, Ointment, Cream

Journal: Cells

Article Title: Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives

doi: 10.3390/cells13050425

Figure Lengend Snippet: Current therapeutics for atopic dermatitis treatment [ 42 , 98 , 103 , 104 , 105 ].

Article Snippet: , Topical , Small molecule , Delgocitinib , Leo Pharma , JAK1 , IIB , NCT03683719.

Techniques: Activation Assay, Activity Assay, Membrane, Injection